Novartis Ag (NVSEF) Assets Average (2009 - 2010)
Novartis Ag's (NVSEF) quarterly Assets Average came in at $95650000.0 billion in Q1 2010, up 245350529553560.2% year-on-year from N/an in Q1 2009, and up 100.3% quarter-over-quarter from $47752500.0 billion in Q4 2009.
Novartis Ag (NVSEF) Assets Average (2009 - 2010) Analysis & Trends
Novartis Ag has disclosed Assets Average across 2 years of filings, most recently posting $95650000.0 billion for Q1 2010.
- Assets Average for Q1 2010 came in at $95650000.0 billion, up 245350529553560.2% year-over-year; the trailing twelve-month figure through Mar 2010 was $95650000.0 billion (up 245350529553560.2% YoY), and the FY2025 annual result was $106.6 billion, up 5.44% from the prior year.
- Assets Average came in at $95650000.0 billion for Q1 2010 at Novartis Ag, up from $47752500.0 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $95650000.0 billion in Q1 2010 to a low of $38985.0 in Q1 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 83.03 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 114.53 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 200.05 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 135.21 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 88.26 Bn |
| 10 | Novartis Ag | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2010 | 95,650,000.00 Bn |
| Dec 31, 2009 | 47,752,500.00 Bn |
| Sep 30, 2009 | 87,480.00 |
| Jun 30, 2009 | 81,122.00 |
| Mar 31, 2009 | 38,985.04 |